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Abstract 
 
Dok-4 is a recently identified member of the Dok family of adaptor proteins, which are 
characterized by an amino-terminal pleckstrin homology domain (PH), a phosphotyrosine 
binding domain (PTB) and a carboxy-terminal region containing several tyrosines and poly-
proline-rich motifs. Two members of the Dok family, Dok-1 and Dok-2 have already been 
described as negative regulators in T cells. However, the function of Dok-4, which is also 
expressed in T cells remains unknown. In this study, we report that Dok-4 is phosphorylated 
after TCR engagement and shuttled within the cytoplasm of T cells before being recruited to 
the polarized microtubule organizing centre (MTOC) after the formation of the 
immunological synapse. Loss-of-function experiments using RNAi constructs show that Dok-
4 is a negative regulator of ERK phosphorylation, IL-2 promoter activity and T cell 
proliferation. Exogenous expression of wild-type Dok-4 induces a significant activation of 
Rap1, which is involved in the regulation of ERK. The PH domain of Dok-4 is required both 
for its cytoplasmic shuttling and relocalization as well as for its inhibitory properties on T cell 
activation. Thus, Dok4 represents a novel negative regulator of T cells. 
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Introduction 
Adaptor molecules are proteins containing modular binding domains that are devoid of 
intrinsic enzymatic activity, but that serve as essential scaffolds for the formation of 
multimolecular signaling complexes in a variety of cell lineages, notably in T cells (1). Dok6 
proteins are a growing family of adaptor molecules, containing an amino-terminal pleckstrin-
homology (PH) domain, a central phosphotyrosine binding (PTB) domain and a carboxy-
terminal part with several tyrosine phosphorylation sites leading to interactions with SH2 
domains. The role of the first two identified Dok family members : Dok-1 and Dok-2, has 
been assessed in the T cell lineage (2). These proteins are tyrosine phosphorylated upon TCR 
triggering or the engagement of the costimulatory molecules (3-5). They are potent inhibitors 
of T cell activation via their binding to RasGAP, which regulates Ras activation, but also 
probably via their association with Src and Tec protein tyrosine kinases (PTKs) family 
members (6, 7). 
Overexpression studies involving Dok-1 or Dok-2 molecules provided evidence that these 
adapter proteins inhibit PLCγ-1 and Ras-ERK/MAPK (extracellular signal-regulated kinase / 
mitogen-activated protein kinase) signals and can prevent IL-2 promoter activation (4, 7). 
Knockdown of Dok-1 and Dok-2 in human primary T cells reveals their negative role on T 
cell functions (3). Upon TCR triggering, T cells from mice lacking both Dok-1 and Dok-2 
displayed increased IL-2 production, as well as proliferation (8).  
Additional five members of this Dok-related family have been identified and named from 
Dok-3 to Dok-7 (9-16). Among these members, only the gene encoding for Dok-4 is 
expressed in resting T cells (14). Based on analysis of phylogenetic trees and exon/intron 
structure of Dok family members, Dok-4 is part of a group that is distinct from that including 
Dok-1 and Dok-2. In non-immune cells, Dok-4 appears to be a substrate of c-Ret or insulin 
receptor tyrosine kinase and Src protein tyrosine kinase family members (11, 12). Functional 
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studies of Dok-4 have yielded conflicting results with two reports claiming that it enhanced 
Ret or insulin receptor-mediated ERK activation (11, 12) and one other report finding that it 
inhibited Ret and Src PTKs-mediated activation of the ERK substrate: Elk-1 (13). These 
apparent discrepancies may relate to differences in cell types, stimuli, and readouts used in the 
various studies. In Ret signalling, Dok-4 leads to activation of the small G protein Rap1, 
which induces a sustained activation of ERK in nerve cells (17). Therefore, it would be useful 
to extend the studies of Dok-4 to other cell types that expressed it, including T cells, where its 
function remains unknown. Here, we investigated if Dok-4 could be a substrate of the PTKs 
involved during T cell activation. We report that Dok-4 accumulates in an intracellular 
vesicular compartment that is recruited to the polarized MTOC (microtubule organising 
centre) during T cell activation and that it requires its PH domain to adopt this particular 
localization. The PH domain was also necessary for Dok-4 ability to inhibit ERK activation 
and IL-2 promoter activity in T cells. 
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Material and Methods 
 
Culture cells and transfection 
Jurkat JA16 T cell subclone and Raji B cell lymphoma were grown in RPMI 1640 medium 
supplemented with 10 % fetal calf serum, 2 mM L-glutamine, and 1 mM sodium-pyruvate. L 
cells expressing human B7.1 (B7.1 L cells) were cultured in Dulbecco’s modified Eagle’s 
medium supplemented with 10 % fetal calf serum, 2 mM L-glutamine and 1 mM sodium-
pyruvate (18). Hut-78 T cells were grown in RPMI 1640 medium supplemented with 10 % 
fetal calf serum (3). 
PBMC from healthy donors (Etablissement Français du Sang, Marseille, France) were 
isolated on Ficoll-Hypaque (Pharmacia, Uppsala, Sweden) gradients before purification of the 
CD4+ T cell subset using the naïve CD4+ T cell isolation kit (Miltenyi Biotec, Paris, France). 
 
Plasmid constructs 
The construct βDNA4HADok-4 (Dok-4) corresponding to the wild-type full-length human 
Dok-4 cDNA tagged with HA epitope in the 5’ end, was generated by subcloning of pGEM-T 
easy vector containing HA tagged Dok-4, described previously (14), into the βDNA4 vector, 
using the restriction site NotI. The βDNA4 vector corresponds to the pCDNA3 vector 
(Invitrogen, Cergy Pontoise, France) where its promoter region has been replaced by the 
promoter region of chicken β-actin (7). Expression plasmid βDNA4HA-ΔPHDok-4 
(ΔPHDok-4), containing the human Dok-4 cDNA tagged with HA epitope in the 5’ end 
lacking the PH domain (deletion of aa 1-119), was generated by PCR amplification of 
βDNA4HADok-4 using the following primers: sense primer 5’-
atgtacccatacgacgtcccagactacgctagtctgggagaacctgacctc-3’ (containing HA epitope), antisense 
primer 5’-tcactgggatggggtcttggcctcac-3’. 
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 Green Fluorescence Protein (GFP) fusion protein expression vectors, Dok4-GFP and 
ΔPHDok4-GFP were obtained by removing HA epitope and stop codon from 
βDNA4HADok-4 and βDNA4HA-ΔPHDok-4 respectively, and introducing cDNAs into the 
BamHI/KpnI sites of the pEGFP-N1 vector (Clontech, Palo Alto, CA). 
The PH domain tagged GFP (PHDok4-GFP) (aa 1-122) was amplified from βDNA4HADok-
4 with the following primers: sense primer 5’-ccgaattccatggcgaccaatttcagtg-3’ and antisense 
primer 5’-cggtggatcccgtcccagactgatgtcgttga-3’. The PCR product was subcloned into 
BamHI/KpnI sites of pEGFP-N1 expression vector. The expression vector Dok4PTB*-GFP 
encodes for a Dok4 -GFP fusion protein containing point mutations into the PTB domain of 
Dok-4, corresponding to the substitution of Arginine 185 and 186 in Alanine (R185/186A). 
These mutations were previously described for Dok-1 (19). They were obtained using 
QuickChange® system (Stratagene, Amsterdam, NL) as from the Dok4-GFP expression 
vector, with the following primers sense 5’-ccctctgctcactggccgcctatggccggg-3’ and antisense 
5’-gcatcccggccataggcggccagtgagcag-3’ (corresponding mutations R185/186A are underlined). 
The expression vector Dok1-GFP encoding for a Dok1-GFP fusion protein was generated by 
PCR amplification from βDNA4HADok-1 using the following primers: sense 5’-
agatctcgagctatggacggggctgtgatggag-3’ and anti-sense 5’-
ggtcaagtctgagggttccaccgtcgacggtaccgcg-3’. The PCR products were sequenced and cloned in 
pEGFP-N1 XhoI/KpnI.  
The promoter assay plasmids pIL-2-Luc composed of IL-2 promoter, fused to firefly 
luciferase reporter gene and pβ-actin-Rluc composed of β-actin promoter, fused with Renilla 
luciferase gene were previously reported (20). 
For siRNA, the pH1shDNA plasmids were derived from the pH1-XhoI plasmid (a descendant 
of pBlueScript KS+) and contained a XhoI-flanked fragment containing the human H1 
promoter amplified by PCR from human blood mononuclear cell genomic DNA, the template 
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small hairpin DNA (shDNA) sequences encoding siRNAs. The hairpins contained the 19 nt 
sense sequence of the target transcript which was separated by a 9 nt loop from the 19 nt 
antisense sequence of the target mRNA and followed by 5 thymidines as a termination signal, 
as previously described (21).  All constructs were verified by sequence analysis. Two 
sequences for the hairpins RNA were shown: 
5’ccccagacagatcgcttcaatgttcaagagacattgaagcgatctgtctgtttttggaaa3’ (19 nt corresponding to pb 
403- 421) which reduces the expression of Dok-4 (more than 50% in immunoblot analysis, 
data not shown). It corresponds to pBChH1-RNAiDok4. The second sequence 
5’ccccattactcgtatccctgcattcaagagatgcagggatacgagtaatgtttttggaaa3’ (19 nt corresponding to pb 
760- 778) which does not reduce the expression of Dok-4. This plasmid will be used as a 
control in our RNAi experiments (pBChH1-Control). 
 
Antibodies and products 
 
CD3 mAbs 289, OKT3 and CD28 mAb 248 have been already reported (18). Polyclonal anti-
Dok1 antibodies have been described previously (20). Anti-Dok2 mAb was purchased from 
BD Transduction laboratory (Le-Pont-De-Claix, France). Polyclonal anti-Dok4 antibodies 
used in western blot experiments were purchased from Abgent (San Diego, CA) or described 
previously (13). Polyclonal anti-Dok4 antibodies used in immunoprecipitation experiments 
were described previously (13). Anti-phosphotyrosine (PY) 4G10 mAb was purchased from 
Millipore (Molsheim, France). Polyclonal anti-GFP antibodies and anti-αtubulin mAb were 
purchased from Abcam Limited (Cambridge, UK). Anti-γtubulin mAb and anti-Rap1 
antibodies were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Anti-
phospho-ERK, anti-ERK, anti-phospho-PLCγ1, anti-PLC γ1, anti-phospho-JNK, anti-
phospho-p38 polyclonal antibodies were purchased from Cell Signaling Technology, Inc. 
(Danvers, MA). Super-antigen SEE, CellTrackerTM Orange CMTMR (5-(and-6)-(((4-
chloromethyl)-benzoyl-amino)tetramethyl-rhodamine) and Ionomycin were respectively 
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purchased from Toxin Technology Inc. (Sarasota, FL), Molecular Probes (Eugene, OR) and 
Calbiochem (VWR International SAS, Fontenay-sous-Bois, France). PMA and poly-L-lysine 
were purchased from Sigma (St Louis, MO). 
 
Immunofluorescence staining 
To distinguish Raji B cells from Jurkat T cells, Raji cells were preincubated in RPMI 10% 
FCS containing 10 µM CellTrackerTM Orange CMTMR for 30 min at 37 °C, washed and 
resuspended (5.106 cells/ml) in RPMI 50mM Hepes, as indicated. Raji cells were then 
incubated for 20 min with or without 5µg/ml SEE. Transfected Jurkat cells were mixed at a 
2:1 ratio with Raji cells pulsed with or without SEE, and then incubated at 37°C for 45 min. 
After stimulation, the cells were deposed onto poly-L-lysine coated coverslips, let sediment 
for 3 min, and then centrifugated at 300 rpm for 1 min. The conjugates were fixed for 5 min in 
methanol. As indicated, immunofluorescence staining was performed. Cells were 
permeabilised in PBS 0.1% Triton for 10 min and saturated in PBS 5% BSA for 20 min. The 
staining with the appropriate antibodies (at the dilution 1:500 in PBS 5% BSA) was 
performed for 20 min, using goat anti-mouse Alexa 594 as secondary antibody (Molecular 
Probes Inc., Eugene, OR). Slides were mounted with fluorescent mounting medium (Dako 
Corporation, Carpinteria, CA). Images were taken and processed using a confocal microscope 
(LEICA TCS NT Confocal Microscope, Heidelberg, Germany).  
 
Stimulation and cell lysis 
 
Jurkat cells (10.106) were stimulated at 37°C in RPMI 50mM Hepes. Stimulations were 
carried out for the indicated times with Raji cells (ratio 2:1) pulsed or not for 20 min at 37°C 
with SEE at 5µg/ml, CD3 mAb 289 at 10µg/ml, CD28 mAb CD28.2 at 10µg/ml or CD28 
ligands expressed at the surface of murine L cells (L-B7.1, ratio 2:1). The cells were pelleted 
in a microcentrifuge and lysed in buffer containing 50 mM Hepes (pH 7.4), 1% Nonidet P-40, 
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150 mM NaCl, 20 mM NaF, 20 mM iodoacetamide, 1 mM phenylmethylsulfonyl fluoride, 1 
µg/ml protease inhibitors (protease inhibitors cocktail, Sigma, St Louis, MO) and 1 mM 
Na3VO4 for 10 min at 4°C, then centrifugated at 13000 rpm for 10 min at 4°C. 
For fractionation experiments, the pellets were lysed using the ProteoExtractTM Subcellular 
Proteome Extraction Kit™ (Calbiochem, VWR International SAS, Fontenay-sous-Bois, 
France), according to the manufacturer’s instructions. The efficiency of subcellular 
fractionation from the Jurkat T cell lysates has been investigated by SDS-PAGE and 
immunoblotting of selected marker proteins. The CD28 molecule was exclusively found in 
the membrane fraction, the heat shock protein (HSP)-90 was detected in the cytosol and 
nucleus fractions, the myc protein was detected in the nucleus fraction and cytoskeleton 
compounds such as actin, vimentin and α /γ-tubulin were present in both cytoskeleton and 
cytosol fractions (data not shown). 
 
Immunoprecipitation and western blotting 
 
For immunoprecipitation, lysates were clarified and incubated with purified anti-GFP or anti-
Dok4 polyclonal antibodies coupled to protein A-Sepharose, for 2 h at 4 °C. 
Immunoprecipitates were washed two times in 1 ml of lysis buffer and then boiled in reducing 
SDS gel sample buffer for 5 min. Samples were resolved by standard 10% SDS-
polyacrylamide gels. 
For immunoblotting, membranes were blocked and probed with specific antibodies. Blots 
were then incubated with the appropriate secondary antibodies, anti-rabbit IgG or anti-mouse 
IgG (Amersham Biosciences Ltd, UK), both conjugated with horseradish peroxidase. 
Immunoreactive bands were visualized by enhanced chemiluminescence (Amersham 
Biosciences Ltd, UK). Protein bands on Western blots were quantified with the ImageJ 
software. 
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Rap assays 
Rap activity was determined as described previously using a GST-RalGDS-RBD fusion 
protein (22). Briefly, Jurkat cells (10 x 106) were stimulated as indicated with 10 μg/ml CD3 
mAb (289), lysed in standard NP40 buffer and clarified by centrifugation at maximal speed in 
an Eppendorf centrifuge for 10 min at 4°C. Two μg of purified GST-RalGDS-RBD coupled 
to glutathione-sepharose beads were added to the supernatant and incubated at 4°C for 60 
min. Beads were washed four times in lysis buffer and denaturated with SDS. 
 
Luciferase assays 
Jurkat cells (10 x 106) were electroporated at 960 μF and 250 V using a Bio-Rad Gene Pulser 
with 12 μg of pIL-2-Luc or NF-AT-Luc plasmid, 1 μg of pβ-Actin-Rluc, and 15 μg of the 
other expression plasmids. Stimulations with APC were carried out for 8 h with Raji cells 
(ratio 1:1) pulsed for 20 min at 37°C with SEE at 10 ng/ml. Stimulation with antibodies were 
carried out for 16 h, using CD28 mAb (248; ascites fluid at a 1:400 dilution) and CD3 mAb 
(289; ascites fluid at a 1:4000 dilution). Stimulations with drugs were carried out for 16 h, 
using PMA (50 ng/ml) and Ionomycin (2 µg/ml). Following cell lysis, proteins were 
quantified by Bradford reagent (Bio-Rad), and 30 μl of cell lysates were then subjected to 
dual luciferase reporter assay according to the manufacturer’s instructions (Promega France 
SARL, Charbonnières, France). Results were corrected by the activity of firefly luciferase 
standardized by that of Renilla luciferase and quantification of proteins in lysates. 
 
 
CD69 expression and proliferation assay 
CD4+ PBL-T cells were transfected with the Amaxa Nucleofector technology (Köln, 
Germany) according to the manufacturer’s instructions and were used 18 h after transfection 
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(http://www.amaxa.com/). CD4+ T cells (105 cells/well) were plated in Cellstar U-bottom 96-
well culture plates (Greiner Bio-One SARL, Poitiers, France) and left unstimulated or 
stimulated with CD3 mAb (OKT3 at 0.5 µg/ml) plus CD28 mAb (CD28.2 at 0.5 µg/ml) or 
PMA at 1 ng/ml plus Ionomycin at 1µg/ml. After 24 h of culture, T cells were incubated with 
PE-conjugated CD69 mAb from BD Biosciences (Pont-de-Claix, France). The detection of 
CD69 expression was done by flow cytometry. After 72 h of culture, wells were pulsed with 1 
µCi [3H]-thymidine (Amersham France, Les Ulis, France) for the remaining 24 h and then 
harvested onto glass fiber filters. Thymidine incorporation was measured in a direct beta 
counter (Matrix 9600, Packard Instruments, France). 
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Results 
Expression and intracellular localization of Dok-4 proteins in T cells 
We have previously reported DOK4 gene expression in resting T cells (14). An anti-Dok4 
polyclonal antiserum (see “Materials and Methods”) was produced to determine the levels of 
Dok-4 protein in cells including T cells. COS cells transiently transfected or not with an 
expression vector containing the Dok-4 cDNA demonstrated the specificity of this antibody. 
As shown in Fig. 1A, strong expression of a 37 kDa protein, consistent with the expected MW 
of Dok-4, was detected in lysates from Dok4-transfected compared to control COS cells. The 
weak signal detected in non-transfected COS-7 cells was thought to correspond to 
endogenous Dok-4 expression, which had been previously reported in several epithelial cell 
lines (13). Dok-4 protein was also detected in peripheral blood T cells (PBL-T) and in the 
Jurkat T cell line confirming previous mRNA expression data (14). To determine the 
subcellular localization of Dok-4 in T cells, three different fractions of Jurkat T cell lysates 
corresponding to cytosol, membranes or cytoskeleton, were analyzed by anti-Dok4 
immunoblotting (Fig. 1B, top panel). Endogenous Dok-4 was detected only in the cytosol and 
cytoskeleton fractions and was absent from membranes. This distribution pattern paralleled 
that of actin, vimentin and α /γ-tubulin that are present in both cytoskeleton and cytosol 
fractions (data not shown). Unfortunately, using different polyclonal anti-Dok4 antibodies, we 
were not able to detect the endogenous Dok-4 protein in T cells by confocal microscopy. To 
determine the intracellular localization of Dok-4, we produced a Dok4-GFP fusion protein, 
which we expressed in Jurkat T cells. Anti-GFP immunoblots confirmed that the transiently 
expressed Dok4-GFP was largely contained in the cytosol and in the cytoskeleton fractions 
like the endogenous protein (Fig. 1B, top versus bottom panel). Under confocal microscopy, 
Dok4-GFP was primarily localized in a condensed area of Jurkat T cell cytoplasm (Fig. 1C). 
Since Dok-4 contains a PH domain that might be recruited by phosphoinositides, localization 
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experiments were duplicated in a T cell line with a normal phosphatidylinositol 3-kinase 
(PI3K) activation, Hut-78. Consistent with the previously reported insensitivity of the Dok-4 
PH domain to the activation of PI3K (23), a similar distribution of Dok4-GFP was observed 
in both Jurkat and Hut-78 T cells (Fig. 1C). Notably, the level of Dok4-GFP overexpression 
in these experiments was moderate, as documented by comparison of the 62 kDa Dok4-GFP 
fusion protein versus the 37 kDa endogenous Dok-4 signal, on the same immunoblot (Fig. 
1D). These observations confirm that Dok-4 is expressed in specific compartments in T cells, 
prompting further investigation into the effect of T cell activation upon Dok-4.     
 
Dok-4 is tyrosine phosphorylated upon TCR stimulation 
Other members of Dok family such as Dok-1 are substrates of protein tyrosine kinases (PTKs) 
in T cells (4, 7, 24). In Jurkat T cells, Dok-1 is prominently tyrosine phosphorylated upon 
engagement of CD28 by its B7-1 (CD80) ligand, but poorly phosphorylated upon TCR 
stimulation with CD3 mAbs (25). Therefore, we examined the tyrosine phosphorylation state 
of Dok-4 under TCR or CD28 stimulation. Jurkat cells were stimulated with CD3 mAbs or 
with L cells expressing B7-1 ligand. Lysates obtained from these cells were subjected to 
immunoprecipitation with anti-Dok4 (Fig. 2A, top panels) or anti-Dok1 (Fig. 2A, bottom 
panels) antibodies followed by anti-phosphotyrosine immunoblotting. As previously 
described, Dok-1 was more prominently phosphorylated upon CD28 stimulation than TCR 
stimulation (Fig. 2A, bottom panels). In contrast, Dok-4 was tyrosine phosphorylated only 
when the TCR/CD3 complex was stimulated, though detection of this phosphorylation 
required long exposure of the immunoblots. TCR-mediated phosphorylation was also 
detectable in Hut-78 T cells (supplementary Fig. 1). To determine the phosphorylation state of 
Dok-4 during TCR- mediated cell-cell contacts, Jurkat T cells expressing Dok4-GFP or Dok1-
GFP were activated by superantigen (SEE)-pulsed Raji B cells as APCs. Cell lysates were 
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subjected to immunoprecipitation with anti-GFP antibodies followed by anti-phosphotyrosine 
immunoblotting. Basal tyrosine phosphorylation of both overexpressed Dok-1 and Dok-4 
proteins was detectable in unstimulated Jurkat cells (Fig. 2B). As previously described (25), 
tyrosine phosphorylation of Dok-1 increased more prominently in Jurkat T cells in the 
absence than in the presence of a TCR stimulus (Fig. 2B, bottom panels). In contrast to Dok-
1, tyrosine phosphorylation of Dok-4 was most strongly increased upon presentation of SEE 
by Raji B cells (Fig. 2B, top panels). Dok-4 phosphorylation was still detectable after 20 min 
of contact with SEE-pulsed Raji B cells (supplementary Fig. 2). Thus, these data suggest that 
the Dok-4 protein is phosphorylated upon TCR engagement. 
 
Dok-4 relocates to the T cell MTOC during APC contact. 
Several intracytoplasmic PTK substrates are recruited to the T cell plasma membrane in the 
context of a T cell – APC contact (26, 27). The cell contact zone has been termed the 
"Immunological Synapse" (IS) (28). To determine whether Dok-4 is recruited to the IS, we 
analyzed by confocal microscopy, cell contacts between Jurkat T cells expressing Dok4-GFP 
and SEE-pulsed Raji B cells labelled in red with a celltracker dye (Fig. 3A). Twenty minutes 
after contact, Dok-4 protein was located in an intracytoplasmic compartment opposite to the 
IS. More prolonged contacts (45 min) resulted in the relocalization of Dok-4 in close 
proximity to the IS. This change in Dok-4 localization did not occur in the absence of antigen, 
suggesting that it was induced by TCR stimulation. This late distribution pattern evoked 
similarities with a polarized MTOC, which has been described before in this position (29). To 
determine whether Dok-4 was located within the MTOC, the centrosomal protein γ-tubulin, a 
key factor in microtubule nucleation, was used as a marker (30). In support of Dok-4 
localization in the MTOC, we found that, in cell fractionation experiments, Dok-4 and γ-
tubulin presented the same distribution pattern (Fig. 3B). To confirm this, confocal analysis 
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was performed in cell conjugates formed between Dok4-GFP-transfected Jurkat T cells and 
SEE-pulsed Raji B cells. In unstimulated T cells, γ-tubulin was condensed in a cytoplasmic 
dot-like structure typical of a MTOC, whereas Dok-4 was in a distinct compartment in close 
proximity to the MTOC (Fig. 3C, top panels). Upon contact with SEE-pulsed Raji B cells 
(time of contact: 20 - 45 min), a polarized MTOC was detected in the vicinity of the IS on 
both T cell and APC side (Fig. 3C, middle and bottom panels). During the early phase of cell 
contact formation, Dok-4 was preferentially found opposite to the IS and MTOC in a 
membrane or sub-membrane compartment (Fig. 3C, middle panels). Later on, Dok-4 re-
localized within the MTOC itself (Fig. 3C, bottom panels). Upon synapse formation, tyrosine 
phosphorylation of Dok-4 was consistently detectable until Dok-4 joined the polarized 
MTOC, at which point Dok-4 was no longer phosphorylated (supplementary Fig. 2 & Fig. 
3D). These results indicate that Dok-4 is specifically shuttled during T cell activation, being 
first excluded from the IS, but then moving back to its vicinity into the polarized MTOC after 
a phase of transient recruitment at the plasma membrane (Fig. 3C & Fig. 3D). Nocodazole 
treatment (a microtubule-disrupting drug) confirmed that Dok-4 migration to the vicinity of 
the IS was dependent upon microtubule network formation (supplementary Fig. 3). 
 
The PH domain regulates Dok-4 localization in T cells 
Dok-4 contains two protein:protein interaction domains, the PH and PTB domains (11, 12, 
14). Both domains are important for Dok-4 plasma membrane localization in epithelial cells 
(13). To test the role of these domains on Dok-4 localization in T cells, we generated different 
mutants of Dok-4 fused to GFP, lacking either the PH domain (ΔPHDok4-GFP) or the PTB 
and the carboxy terminal part (PHDok4-GFP). We also developed a PTB mutant of Dok-4 
containing a substitution of critical residues of the PTB domain (Dok4PTB* -GFP), these 
arginine to alanine mutations are usually able to abolish the binding functions of the PTB 
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domains as described for the PTB domain of Dok-1 (19). The localization of the different 
Dok-4 mutants in unstimulated Jurkat T cells or in contact with SEE-pulsed Raji B cells, was 
determined by confocal microscopy. Deletion of the PH domain ΔPHDok4-GFP) resulted in a 
diffuse cytosolic distribution in stimulated or unstimulated Jurkat cells (Fig. 3D, top panels). 
The isolated PH domain of Dok-4 (PHDok4-GFP) was localized in a cytosolic and membrane 
fraction, and was not recruited to the MTOC during IS formation (Fig. 3D, middle panels). 
Point mutations in the PTB domain (Dok4PTB* -GFP) did not alter the distribution of Dok4 
(Fig. 3D, bottom panels). These results indicate that the PH domain of Dok4 is necessary for 
the basal localization of Dok4, and for its recruitment in the MTOC compartment during T 
cell / APC junction.  
 
Dok-4 regulates T cell signaling  
To determine the role of the Dok-4 molecule in signaling events downstream of TCR 
stimulation, we analyzed ERK1/2 activation in Jurkat cells upon contact with SEE-pulsed Raji 
B cells. Different research groups reported that Dok-4 was involved in ERK activation and 
downstream transcription factors such as Elk-1 (11-13, 17). However studies found Dok-4 to 
be an activator of ERK pathway in CHO cells or nerve cells (11, 12, 17) and other studies 
found that Dok-4 inhibited the activation of Elk-1 in Caco-2 epithelial cells (13, 31). To 
resolve this issue in T cells, we developed an alternative approach to knock down Dok4 
expression using RNA interference (RNAi). As shown in Fig. 4A, transfection with a plasmid 
containing a Dok-4 RNAi sequence resulted in almost complete inhibition of the endogenous 
expression of Dok-4 in Jurkat T cells after one day whereas transfection with an empty vector 
or a construct containing an inefficient Dok-4 RNAi sequence did not affect Dok-4 
expression. Expression of Dok-1 and Dok-2 was not affected in Dok-4 RNAi-treated cells 
(Fig. 4A, middle and bottom panel), confirming the specificity of Dok-4 RNAi. In Jurkat cells 
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stimulated by Raji B cells, ERK phosphorylation was detected only upon presentation of SEE 
(Fig. 4B, top panels).  In Dok-4 RNAi-treated Jurkat cells, TCR engagement resulted in 
enhanced phosphorylation of ERK as compared to control RNAi-treated cells. In contrast, 
tyrosine phosphorylation of PLC-γ, was not altered by Dok-4 RNAi (Fig. 4B and 4C, bottom 
panels). The other MAPK pathways involved in T cell activation were also examined and 
relative protein phosphorylation level was calculated (supplementary Fig. 4). This showed 
that JNK phosphorylation was mildly altered by Dok-4 RNAi (JNK phosphorylation is 
decreased at 30 min), whereas surprisingly p38 MAPK phosphorylation was decreased in the 
presence of downregulated Dok-4 (Fig. 4C, center panels).  
In complement to the Dok-4 RNAi approach, we examined the effect of Dok-4 
overexpression on MAPK pathways in Jurkat T cells.  As shown in Fig. 5A, overexpression 
of Dok-4 markedly decreased ERK phosphorylation induced by CD3 plus CD28 engagement 
(relative phosphorylation intensity is shown in supplementary Fig. 5). Consistent with Dok-4 
RNAi experiments (Fig. 4C), Dok-4 overexpression appeared to slightly increase JNK and 
p38 MAPK phosphorylation under CD3 plus CD28 co-stimulation (Fig. 5A and 
supplementary Fig. 5). In contrast to wild-type Dok-4, overexpression of the PH-deleted 
mutant of Dok-4 induced an increase of ERK activation and it had little effect in general on 
activation of the other MAPK pathways (Fig. 5A, right side and supplementary Fig. 5). Taken 
together these results suggest that, in T cells, Dok-4 negatively regulates ERK activation, but 
positively regulates p38 MAPK activation. Because Dok-4 has been reported to activate the 
Ras-related GTPase Rap1 in nerve cells (17) and because Rap1 negatively regulates ERK 
activativation in T cells (32), we investigated the impact of Dok-4 overexpression on Rap1 
activation in T cells. Rap1 activity assays were performed on cell lysates of Jurkat T cells 
transfected with wild-type Dok-4 or the PH-deleted mutant of Dok-4 (Fig. 5B). Rap1 was 
activated upon CD3 stimulation and this activation was enhanced in the presence of Dok-4 
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overexpression. In contrast, overexpression of the PH-deleted mutant of Dok-4 blocked Rap1 
activation in TCR-activated T cells. Thus, activation of Rap1 by Dok-4 could plausibly 
account for our observation of Dok-4-mediated inhibition of ERK in T cells.  
 
Dok-4 inhibits T cell function  
To further determine the role of Dok-4 on T cell activation, we examined IL-2 promoter 
activation. We had previously shown that SEE-pulsed Raji B cells induced Jurkat cells to 
transcribe a reporter luciferase gene under the control of an IL-2 promoter sequence (33). In 
RNAi-treated Jurkat cells, a decrease of approximately 90% in Dok-4 protein expression was 
achieved (Fig. 6A, right panels) and was accompanied by increased activity of the IL-2 
promoter upon contact with SEE-pulsed Raji B cells (Fig. 6A, left panel). These results were 
consistent with the observed effect of Dok-4 RNAi on ERK activation (Fig. 4B and 4C). 
Conversely, overexpressing Dok-4 in Jurkat cells (Fig. 6B) reduced IL-2 promoter activity 
induced by CD3+CD28 co-stimulation. However, Dok-4 overexpression had no impact on IL-
2 promoter activity induced by a stimulus (PMA + Ionomycin treatment) that bypasses the 
early steps in TCR signaling. In contrast to wild-type Dok-4, overexpression of the PH-
deleted mutant of Dok4 did not inhibit IL-2 promoter activation (Fig. 6B, left panel). Anti-HA 
epitope tag immunoblotting confirmed that similar levels of wild-type Dok-4 (HADok4) and 
PH-deleted mutant (HAΔPHDok4) were obtained (data not shown). Therefore, deletion of the 
PH domain abolished the repressive action of Dok-4 on IL-2 promoter activity.  
Primary CD4+ PBL-T cells isolated from human peripheral blood were also examined. Dok-4 
siRNA sequences were introduced in these cells by nucleofection technology, resulting in an 
approximately 60% reduction in Dok-4 expression after 24 hours (Fig. 6C, right panel). Dok-
4 inhibition resulted in an increase of CD69 cell surface expression (Fig. 6C, left panel) and 
of T cell proliferation (Fig. 6D) in response to CD3+CD28 co-stimulation. Altogether, results 
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show that Dok-4 is a negative regulator of ERK phosphorylation, IL-2 promoter activation 
and proliferation in T cells. 
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Discussion 
In this report, we demonstrate that a novel Dok family member Dok-4, is expressed in specific 
cytoplasmic compartments in T cells, is phosphorylated in response to TCR engagement and 
negatively regulates T cell activation.  
Having previously shown that Dok-4 mRNA is expressed in resting T cells (14), we have now 
confirmed that Dok-4 protein is expressed in these cells and that it undergoes tyrosine 
phosphorylation upon TCR stimulation (Fig. 2 and supplementary Fig. 1). Of note, as 
compared to phosphorylation of Dok-1 and 2, which is quite robust following T cell 
stimulation (3), tyrosine phosphorylation of Dok-4 was more subtle and was consistently 
more difficult to detect. In Dok-1 and Dok-2, most sites of tyrosine phosphorylation appear to 
be contained within the C-terminal region. In contrast, most tyrosine residues within the C-
terminal region of Dok-4 sequence are predicted to be poor substrates for PTKs (data not 
shown). Indeed, the deletion of this C-terminal region did not alter the tyrosine 
phosphorylation of Dok-4, suggesting that some tyrosine residues in the PH or PTB domain 
are accessible to the PTKs (13). Among the PTKs so far shown to phosphorylate Dok-4 (11-
13), only members of the Src family, such as Fyn, are involved in TCR signaling events.  
Subcellular localization might be a limiting factor for tyrosine phosphorylation of Dok-4 in T 
cells. Dok-4 was primarily located at the vicinity of the MTOC, as identified by γ-tubulin 
staining (Fig. 3C). Both γ-tubulin and endogenous Dok-4 accumulated in cytoskeletal 
fractions (Fig. 3B). Following SAg presentation, Dok-4 was initially located at the distal pole 
of the immunological synapse. Later on, Dok-4 accumulated at the polarized MTOC in the 
vicinity of the immunological synapse (Fig. 3). Dok-4 was also transiently detected at the 
plasma membrane (Fig. 3C), which could permit the phosphorylation of Dok-4 by the Src 
kinase members present in the inner leaflet of the plasma membrane (supplementary Fig. 2). 
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However, the exact identity of the subcellular compartments containing the Dok-4 adaptor 
molecule remains under investigation.  
Following a prolonged cell contact, Dok-4 was located at the polarized MTOC (Fig. 3C). 
Several signaling molecules involved in T cell activation, such as protein kinases (like PKCβ, 
FAK, or Pyk-2) colocalize with the MTOC (34, 35). To address the mechanisms responsible 
for targeting Dok-4 to these intracellular compartments, we examined the role of its PH 
domain. PH domains are generally considered as phosphoinositide-binding modules and have 
often been implicated in recruitment of proteins to the plasma membrane (36). Some 
molecules like the four-phosphate-adaptor protein 1 and 2 (FAPP1 and FAPP2) accumulate 
via their PH domains in intracellular compartments such as the trans-Golgi network (37). The 
PH domain of Dok-4 is important to localize Dok-4 at the plasma membrane of the epithelial 
cells (13). Here, we show that, in T cells, Dok-4 localizes to a unique intracellular 
compartment through the action of its PH domain (Fig. 3D). However, an isolated Dok-4 PH 
domain alone could not accumulate in the same intracellular compartments, suggesting that 
cooperation with another region of Dok-4 is required. This is not surprising given evidence 
that other PH domains require the cooperative action of another domain for subcellular 
targeting (38-40). Indeed, Dok-4 itself requires both its PH and PTB domains in order to 
localize at the membrane in epithelial cells (13). However, using a point mutant of the PTB 
domain, we show that the localization of Dok-4 to its unique intracellular compartment in T 
cells appears to be independent of PTB domain function (Fig. 3E). Since specific 
phosphoinositides control the correct location and timing of many trafficking events (41) and 
since PH domains are generally recognizing a variety of phosphoinositides (42), defining the 
phosphoinositide-binding specificity of the Dok-4 PH domain will be important in order to 
identify its role mediating subcellular targeting of Dok-4.  
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Our studies show that, in addition to its role in subcellular targeting, the PH domain is also 
essential to mediate the inhibitory effect of Dok-4 on T cell activation. It has previously been 
suggested that Dok-4 regulates the ERK signaling pathway (11-13), but conflicting results 
exist as to its stimulatory versus inhibitory impact. Using a Dok-4 RNAi strategy as well as an 
overexpression approach, we showed that Dok-4 negatively regulates the activation of ERK 
without altering other key signalling events such as the tyrosine phosphorylation of PLC-γ1 or 
the activation of JNK. How Dok-4 targets the ERK pathway is unclear because, unlike Dok-
1/2, Dok-4 does not bind p120RasGAP, an inhibitor of the Ras/ERK pathway (11). However, 
as had previously been shown in nerve cells stimulated through Ret (17), we found that Dok-4 
activates Rap1 downstream of TCR stimulation in T cells (Fig. 5B). In T cells, Rap1 has been 
generally implicated in the regulation of cell adhesion (43), but it has also been reported to 
antagonize ERK activation in anergic T cells, thus contributing to repression of IL-2 
transcription in these cells (32, 44). To further dissect the inhibitory mechanisms involved in 
Dok-4 action, it will be essential to identify the partner molecules for Dok-4 in T cells, which 
are currently unknown.  
Our findings, taken together with previous studies of Dok-1 and Dok-2 (3, 4, 7, 8), 
demonstrate that the three Dok-related adaptors expressed in resting T cells (Dok-1/ -2 / -4) 
are negative regulators of T cell activation, although they likely perform this function through 
different mechanisms.  
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Figure legends 
 
Figure 1. Subcellular localization of Dok-4.  
(A) Western blot anti-Dok4 was performed on whole cell lysate of Cos7 cells, Cos7 
expressing HADok4, Jurkat cells and peripheral blood T cells (PBL-T).  
(B) Fractionation experiment was performed on Jurkat cells or Jurkat cells transfected with 
Dok4-GFP. 50 µg of lysates were separated by SDS-PAGE and identified by immunoblotting 
with anti-Dok4 antibodies for untransfected Jurkat cells (Dok4 WB, top panel) or anti-GFP 
antibodies for transfected cells (GFP WB, bottom panel). Data are representative of three 
independent experiments.  
(C) Jurkat or Hut-78 cells were transfected with Dok4-GFP. 24 h after transfection, cells were 
plated on poly-L-lysine coated coverslip. 50 GFP+ cells are examined and a representative 
distribution pattern is shown. 
(D) Western blot anti-Dok4 was performed on whole cell lysate of Jurkat or Hut-78 
expressing Dok4-GFP, arrowheads are indicating the position of the endogenous Dok-4 and 
the GFP fusion protein. 
 
Figure 2. Dok-4 is tyrosine phosphorylated upon TCR stimulation.  
(A) Jurkat cells (107) were left unstimulated (NS) or stimulated with CD3 mAb (CD3 
condition) or using a coculture with L cells expressing the human B7.1 (CD28 condition) for 
10 min. Whole cell lysates were immunoprecipitated with anti-Dok4 or anti-Dok1 antibodies, 
separated by SDS-PAGE and probed by immunoblotting with anti-phosphotyrosine mAb (PY 
WB). The membrane was stripped and reprobed with an anti-Dok4 antibody (Dok4 WB). This 
experiment is representative of three independent experiments.  
(B) Jurkat cells were transfected with Dok4GFP or Dok1GFP. 24 h after transfection, cells 
were stimulated for the indicated time with Raji cells pulsed or not with SEE. Whole cell 
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lysates were immunoprecipitated with anti-GFP antibodies, separated by SDS-PAGE and 
probed by immunoblotting with anti-phosphotyrosine mAb (PY WB). The membrane was 
stripped and western blot anti-GFP was performed (GFP WB). This experiment is 
representative of three independent experiments. 
 
Figure 3. Dok-4 recruitment during T – APC contact.  
(A) Jurkat cells were transfected with pDok4GFP. 24 h after transfection, cells were incubated 
for the indicated time with Raji or pulsed SEE-Raji cells. Raji cells were preincubated for 30 
min with CMT-MR. Contacts were plated on poly-L-lysine coverslips. (B) Jurkat cells were 
transfected with pDok4GFP. 24 h after transfection, cells were stimulated for 30 min with 
Raji or pulsed SEE-Raji cells. After fractionation experiments, 50 µg of lysates were 
separated by SDS-PAGE and probed by immunoblotting with anti-GFP, or anti-Dok4 
antibodies. This experiment is representative of at least three independent experiments. (C) 
Jurkat cells were transfected with pDok4GFP. 24 h after transfection, Jurkat cells were 
incubated or not for 45 min with pulsed SEE-Raji cells. Contacts were plated on poly-L-lysine 
coverslips. Immunofluorescence against γ-tubulin was performed. 40-50 GFP+ cells were 
examined for each condition and a representative distribution pattern is shown. (D) Kinetic of 
Dok4GFP localization during conjugate formation. Raji cells were labeled with CMT-MR and 
pulsed with SEE, as described in Materials and Methods. Dok4GFP expressing-Jurkat cells 
and Raji cells were admixed, plated on poly-L-lysine coverslips and spin-down for 2 min at 
1000 rpm to allow synchronization of conjugates formation. At the indicated time, cells were 
fixed in 4% PFA and stained for α-tubulin. Localization of Dok4GFP has been divided and 
scored as follow: (1) Dok4GFP was localized at the back of the cell, not found at the IS 
(black); (2) Dok4GFP was localized along the microtubule, and/or localized both at the back 
and at the IS (bipolar localization) (dark grey); (3) Dok4GFP was exclusively localized at the 
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IS (light grey). Percentages correspond to at least 20 cells examined for each condition. This 
experiment is representative of two independent experiments. (E) Jurkat cells were 
transfected with ΔPHDok4GFP, PHDok4GFP or Dok4PTB*-GFP. 24 h after transfection, 
Jurkat cells were incubated for 45 min with Raji or SEE- pulsed Raji cells. Raji cells are 
preincubated for 30 min with CMT-MR. Contacts were plated on poly-L-lysine coverslips.  
 
Figure 4. Down-expressing Dok-4 induces hyper-activation of ERK1/2. (A) Jurkat cells 
were transfected with pBChH1 (empty vector), pBChH1-RNAiDok4 (containing shDNA 
encoding for a Dok-4 siRNA that downregulates the Dok-4 expression) or pBChH1-Control 
(containing shDNA encoding for a Dok-4 siRNA that does not alter the Dok-4 expression). 24 
h after transfection, cells were left lysed. Whole cell lysates were separated by SDS-PAGE 
and identified by immunoblotting with anti-Dok1, Dok2 and Dok4 antibodies. This 
experiment is representative of at least three independent experiments. (B) Jurkat cells were 
transfected with pBChH1, pBChH1-RNAiDok4 or pBChH1-Control. 24 h after transfection, 
cells were left unstimulated or stimulated for 15 min with Raji cells or pulsed SEE-Raji cells. 
Whole cell lysates were separated by SDS-PAGE and identified by immmunoblotting with 
anti-phospho-Erk1/2 or anti-phospho-PLCγ antibodies. The membrane was stripped and anti-
Erk, anti-PLCγ immunoblots were performed. This experiment is representative of at least 
three independent experiments. (C) Jurkat cells were transfected with pBChH1-Control or 
pBChH1-RNAiDok4. 24 h after transfection, cells were left unstimulated (in contact with 
unpulsed Raji for 15 min) or stimulated for 5, 15 or 30 min with pulsed SEE-Raji cells. Whole 
cell lysates were separated by SDS-PAGE and identified by immmunoblotting with anti-
phospho-Erk1/2, anti-Erk, anti-phospho-JNK, anti-phospho-p38MAPK or anti-
phosphoPLCγ antibodies (Relative protein phosphorylation was calculed and shown in 
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supplementary Fig. 4). The membrane was stripped and anti-Erk, anti-PLCγ immunoblots 
were performed. This experiment is representative of two independent experiments. 
 
Figure 5. Dok-4 overexpression induces a decrease of ERK1/2 activation and a Rap1 
hyper-activation. 
Jurkat cells were transfected with 20 µg empty vector, Dok4-GFP or ΔPHDok4-GFP. After 
24 h of recovery, cells were stimulated with CD3 plus CD28 mAbs (A) for various times (3, 
10, 30 min) and lysed, then the levels of phosphorylated MAPKs were determined by western 
blot analysis with specific antibodies (Relative protein phosphorylation was calculed and 
shown in supplementary Fig. 5). Three independent experiments have been performed. (B) 
Transfected Jurkat cells were stimulated with CD3 mAb for 5 or 10 min, then lysates were 
incubated with GST-RalGDS RBD fusion proteins, beads were washed and finally proteins 
were subjected to western blot analysis for Rap1 (Rap assay, upper panel), total level of Rap1 
was determined from whole cell lysates (Rap total, center panel) or the presence of wild-type 
Dok-4-GFP or PH-deleted Dok-4-GFP were detected after GFP immunoprecipitation 
followed by anti-GFP western blot analysis. The position of both Dok-4 forms was indicated 
by arrowheads (GFP WB, bottom panel). Two independent experiments have been performed. 
 
Figure 6. Down-expressing Dok-4 promotes IL-2 promoter activation and T cell 
proliferation. (A) Jurkat cells were transfected with 10 µg pBChH1or pBChH1-RNAiDok4 
and 10 µg pIL-2-Luc, and 1 µg βactinR-luc. After 16 h of recovery, cells were left 
unstimulated or stimulated for 8 h with an equivalent number of Raji cells or Raji cells pulsed 
with SEE. Three independant experiments have been performed. In control, whole cell lysates 
were separated by SDS-PAGE and identified by immunoblotting with anti-Dok4 and anti-
αtubulin. (B) Jurkat cells were transfected with 10 µg empty vector, Dok4-GFP or ΔPHDok4-
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GFP, and 10 µg pIL-2-Luc, and 1 µg βactinR-luc. After 2 h of recovery, cells were stimulated 
with CD3 and CD28 mAbs, or PMA and Ionomycin. After 18 h of stimulation, luciferase 
assay was performed. Three independent experiments have been performed. (C-D) PBL-Ts 
were transfected with pBChH1 or pBChH1-RNAiDok4. After 24 h of recovery, cells were left 
unstimulated, or stimulated with CD3 and CD28 mAbs, or PMA and Ionomycin. (C) After 1 
day of stimulation, CD69 cell surface expression was examined by flow cytometry and 
expressed as the mean of fluorescence intensity (MFI). Two independent experiments in 
duplicate were performed. To confirm Dok-4 overexpression, cells were lysed and subjected 
to immunoblotting with anti-Dok4 and anti-α tubulin antibodies. (D) After 4 days of 
stimulation, [3H]-thymidine incorporation measurement was performed. Three independent 
experiments in triplicate were performed.  
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